Aims/hypothesis The global epidemic of type 2 diabetes affects women and men equally; however, the relative impact on the cardiovascular (CV) system appears greater for women than men when compared with peers without diabetes. Furthermore, women are often under-represented in CV outcome trials, resulting in less certainty about the impact of CV prevention therapies across the sexes. The EMPA-REG OUTCOME® trial, which included 28.5% women, found that empagliflozin, given in addition to standard of care, reduced the risk of CV death by 38%, heart failure (HF) hospitalisation by 35% and a composite endpoint for incident or worsening nephropathy by 39%. Here we report a secondary analysis of the trial to determine the relative effects of empagliflozin in women vs men. Methods The population studied were individuals with type 2 diabetes (HbA 1c 53-86 mmol/mol [7-10%] and eGFR >30 ml min
Introduction
The global epidemic of type 2 diabetes is expected to affect 642 million individuals by 2040 and impacts women and men equally [1] . It has been postulated that when women develop diabetes, they lose their generally protective effect against cardiovascular (CV) complications. Thus, the relative risk for CV complications is greater in women with diabetes than men when compared with peers without diabetes. This observation may relate to differences in CV risk factors in men and women, influence of sex hormones on CV risk, or sex disparities in the management of diabetes and/or CV risk factors [2] . Moreover and disappointingly, women typically only constitute 25-40% of the study populations in major CV outcome trials [3] [4] [5] . Thus, there may be less certainty about efficacy and safety of CV preventive strategies in women with diabetes. The EMPA-REG OUTCOME® trial, which included 28.5% women, found that empagliflozin, given in addition to standard of care, reduced the risk of CV death by 38% (HR 0.62 [95% CI 0.49, 0.77]; p < 0.001), heart failure (HF) hospitalisation by 35% (HR 0.68 [0.57, 0.82]; p < 0.001) and a composite endpoint for incident or worsening nephropathy by 39% (HR 0.61 [0.53, 0.70]; p < 0.001) vs placebo [5] [6] [7] . As a result of this trial, approval for a CV death prevention indication in individuals with type 2 diabetes and established CV disease was granted by the US Food and Drug Administration and other regulatory authorities. Here we report a secondary prespecified analysis [5] of the trial to determine the relative effects of empagliflozin in women vs men.
Methods
Description of the trial design (NCT01131676) and methodology used has previously been reported [5] [6] [7] . In brief, the population studied was individuals with type 2 diabetes (HbA 1c 53-86 mmol/mol [7-10%] and eGFR >30 ml min
) who had established atherosclerotic CV disease. Individuals were randomised to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care. Throughout the trial, investigators were encouraged to treat CV risk factors (including dyslipidaemia and hypertension) to achieve the best available standard of care according to local guidelines. All CV outcome events were
prospectively adjudicated by independent and blinded clinical events committees. For the renal outcomes analysed, serum creatinine and urinary albumin in spot urine samples obtained during regular study visits were measured in central laboratories with the use of standardised procedures. We used the modification of diet in renal disease (MDRD) formula to estimate the eGFR. Safety was assessed on the basis of adverse events that occurred during treatment or within 7 days after the last dose of study drug, and collected as previously reported [5] [6] [7] .
Cox proportional hazards models were used to assess between-group differences in the risk of an outcome after adjustment for study group, age, sex, baseline BMI, HbA 1c , eGFR and region. We present overall HR according to sex and the interaction p value considering the interaction of treatment × sex for CV death, HF hospitalisation and the predefined composite renal outcome. Kaplan-Meier plots are presented to display events over time; adverse events are expressed as proportions. Post hoc power considerations were derived using ADDPLAN (version 6.1.1, 2014, ICON, www. iconplc.com/innovation/addplan). All study participants gave informed consent prior to enrolment, and the investigations were approved by ethics committees or institutional review boards.
Results
The profile at baseline ( Prior coronary artery disease was less common in women (62.8% vs 80.7%), but women had a more frequent history of stroke (31.6% vs 20.0%). History of HF was similar (10.5% vs 9.9%).
Effects of empagliflozin on reducing BP, HbA 1c , weight and waist circumference were of similar magnitude regardless of sex (data not shown). The annualised incidence rate for women in the placebo group was numerically lower than that in men for CV death (1.58% vs 2.19%), numerically higher for HF hospitalisation (1.75% vs 1.33%), and similar for renal events (7.22% vs 7.75%). Empagliflozin reduced the primary composite endpoint (CV death, non-fatal stroke, non-fatal myocardial infarction) relatively by 14% (Fig. 1a,b) by a similar degree, irrespective of sex (interaction p value 0.8114). We did not detect any effect modification by sex within the statistical power restrictions of the analysis for CV death, HF hospitalisation and incident or worsening nephropathy (Fig. 1a, c-e; interaction p values 0.32, 0.20 and 0.85, respectively). Separation of the incidence curves for these events were generally early and risk reduction with empagliflozin vs placebo persisted for the trial's duration (Fig. 1b-e) . Post hoc power considerations are provided in ESM Table 3 .
Empagliflozin was well tolerated by women, with no remarkable difference between empagliflozin and placebo for most adverse events assessed, including urinary tract infections. Genital infections, which were more common in women than in men in both treatment groups, were increased with empagliflozin treatment. In women this was observed in 2.5% in the placebo group and 10.0% in the empagliflozin group while in men, 1.5% and 2.6%, respectively, consistent with the known safety profile of sodium-glucose cotransporter-2 (SGLT2) inhibition. Nevertheless, discontinuation of the study drug due to this adverse event was infrequent. For every 1000 women treated with empagliflozin for 3.1 years, there occurred 12 fewer CV deaths, 27 fewer hospitalised HFs and 83 fewer incident or worsening nephropathy events, with 101 more genital infections, in comparison with placebo.
Discussion
Women with type 2 diabetes and established CV disease who were enrolled in the EMPA-REG OUTCOME® trial experienced high CV and renal event rates, in particular hospitalisation for HF that occurred numerically more frequently than in men, emphasising the high impact of diabetes on complications in this group. The numerically higher event rate for HF hospitalisation in women than in men is interesting in light of a similar between-sexes a priori 5 year estimated HF risk using the Health ABC HF risk score [8] , bearing in mind the limitation that our trial was not powered to address sex differences. This observation could be related both to underlying factors specific to women [2] or, as suggested by others [9] , because evidence-based HF therapies a r e u s e d l e s s o f t e n b y w o m e n . I n E M PA -R E G Fig. 1 (a) Forest plot of 3 OUTCOME®, use of glucose-lowering medications, ACEis/ARBs and overall antihypertensive therapy use (albeit characterised by somewhat more diuretic and somewhat less beta-blocker use), was similar in men and women. However, both women and men allocated to placebo had a higher proportion of new prescriptions of such drugs during the trial than those allocated to empagliflozin. Women did have lower use of lipid-lowering and anti-platelet therapies, but neither of these have been associated with HF outcomes. Also, as fewer women than men were current or former smokers, a habit usually associated with increased HF risk [10] , our observation could lend support to the hypothesis of female-specific factors playing a role. Empagliflozin was generally well tolerated, with a higher frequency of genital infections in both sexes, more so both in relative and absolute terms in women. This is congruent with results from previous reports on the use of empagliflozin, which has increased the risk of yeast vaginitis in earlier trials involving women with type 2 diabetes at lower CV risk [11] .
In conclusion, CV death, HF hospitalisation and incident or worsening nephropathy rate reductions induced by empagliflozin were not different between women and men.
